News Story: Full Text
Sponsored By
Cedars-Sinai Medical Center Brain Tumor Program
Please Click On The Above Banner For More Details
Braintumor Website


ADVISORY/FDA Approves Novartis` Unique Leukemia Medication Gleevec (Business Wire)...Novartis today announced that the United States Food and Drug Administration (FDA) approved its drug Gleevec(tm) (imatinib mesylate) as an oral therapy for the treatment of patients with chronic myeloid leukemia (CML) in the blast crisis,...- May 10 3:31 PM ET


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)



Website: http://biz.yahoo.com/bw/010510/0346.html

Posted on: 05/10/2001

"Yahoo - ADVISORY/FDA Approves Novartis' Unique Leukemia Medication Gleevec"
Yahoo! Finance Finance Home - Yahoo! - Help
Business Wire

[ Latest Headlines | Market Overview | News Alerts ]


Related Quotes
^DJI
^IXIC
^SPC
^IIX
^PSE
10910.44
2128.86
1255.18
203.04
756.00
+43.46
-27.77
-0.36
-3.00
-6.30
delayed 20 mins - disclaimer
Thursday May 10, 3:31 pm Eastern Time

Press Release

ADVISORY/FDA Approves Novartis' Unique Leukemia Medication Gleevec

  • (BUSINESS WIRE)--

    Novartis today announced that the United States Food and Drug Administration (FDA) approved its drug Gleevec(tm) (imatinib mesylate) as an oral therapy for the treatment of patients with chronic myeloid leukemia (CML) in the blast crisis, accelerated phase or in chronic phase after failure of interferon-alpha therapy. The effectiveness of Gleevec is based on overall hematologic and cytogenetic response rates. Video and photos coming later.

    You can reach the story directly by going to http://www.newstream.com/cgi-bin/display_story.cgi?2885

    This multimedia news story is for free and unrestricted use on your news information site (and for print or broadcast too). Visit http://www.newstream.com to download video, audio, text, graphics, and photos.

    If you have any questions about the story, or about Newstream.com, please write to us at info@newstream.com.


    Contact:
         Newstream.com, New York
         Les Blatt, 888/560-5578
         info@newstream.com

    Email this story - Most-emailed articles - Most-viewed articles


    Related News Categories: health care, medical/pharmaceutical

    Help


    Copyright © 2001 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
    Copyright © 2001 Business Wire. All rights reserved. All the news releases provided by Business Wire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

    Questions or Comments?
    "


    Click HERE to return to brain tumor news headlines


  • Home | Brain Tumor Guide | FAQs | Find A Treatment
    Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
    Donations | Brain Tumor Centers | Survivor Stories | Temodar®
    Fundraising For Research | Unsubscribe | Contact Us

    Copyright (c) 1993 - 2020 by:
    The Musella Foundation For Brain Tumor Research & Information, Inc
    1100 Peninsula Blvd
    Hewlett, NY 11557
    888-295-4740